Bonell Patiño-Escobar

The paper investigates the CD48-CD244 axis in multiple myeloma, showing CD48 enhances NK-cell activation but contributes to NK exhaustion and poor prognosis.

This study shows that affinity-matured CD72-targeting nanobody CAR T-cells improve in vitro efficacy against CD72-low tumors but show limited in vivo benefit, while CD72 expression remains stable after CD19 resistance in B-cell malignancies.

This paper engineers CCL27 mutants to enhance CAR T-cell efficacy against multiple myeloma by targeting CCR10, achieving results comparable to BCMA CAR-Ts.

Structure-optimized CD27-based CAR-T cells targeting CD70 show >80-fold improved expansion in vivo and offer a potential therapy for high-risk multiple myeloma patients.